{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:12Z","timestamp":1791357852725,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:00:00Z","timestamp":1451952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1053\/j.ajkd.2015.11.021","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T01:50:11Z","timestamp":1453945811000},"page":"861-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"title":["A Novel Hypoxia-Inducible Factor\u2212Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial"],"prefix":"10.1053","volume":"67","clinical-trial-number":[{"clinical-trial-number":"nct00750256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00840320","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00935831","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01047397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01587898","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01587924","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01977482","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01977573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02019719","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard A.","family":"Brigandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coreen","family":"Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Olbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janak","family":"de Zoysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabhadra","family":"Guptha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Smolyarchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven F.","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Borsukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav V.","family":"Marasaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gullipalli","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina Y.","family":"Timokhovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Kolmakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Dobronravov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Packham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Zateyshchikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Arutyunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina V.","family":"Volgina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill S.","family":"Lipatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry V.","family":"Perlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Kumar Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Zagrebelnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya A.","family":"Koziolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narina P.","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia V.","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2015.11.021_bib1","unstructured":"National Kidney Foundation. KDOQI guidelines, executive summaries of 2000 updates. www.kidney.org\/news\/newsroom\/newsreleases\/0173. Accessed September 12,\u00a02014."},{"issue":"2","key":"10.1053\/j.ajkd.2015.11.021_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.1984.36","article-title":"Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency","volume":"25","author":"McGonigle","year":"1984","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2015.11.021_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1985.109","article-title":"Anemia of end-stage renal disease (ESRD)","volume":"28","author":"Eschbach","year":"1985","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.11.021_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin-a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.11.021_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.03840907","article-title":"Novel erythropoiesis-stimulating agents: a new era in anemia management","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.11.021_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14656566.2012.658369","article-title":"An expert opinion on the current treatment of anemia in patients with kidney disease","volume":"13","author":"Locatelli","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2015.11.021_bib7","first-page":"iv19","article-title":"Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data","volume":"22","author":"Carrera","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2015.11.021_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/nep.12214","article-title":"Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis","volume":"19","author":"Roger","year":"2014","journal-title":"Nephrology"},{"issue":"4","key":"10.1053\/j.ajkd.2015.11.021_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/eje.0.1390367","article-title":"Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy","volume":"139","author":"Sohmiya","year":"1998","journal-title":"Eur J Endocrinol"},{"issue":"36","key":"10.1053\/j.ajkd.2015.11.021_bib10","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"14","key":"10.1053\/j.ajkd.2015.11.021_bib11","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","article-title":"Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway","volume":"95","author":"Huang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1053\/j.ajkd.2015.11.021_bib12","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1161\/ATVBAHA.107.148551","article-title":"A\u00a0novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia","volume":"27","author":"Nangaku","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1053\/j.ajkd.2015.11.021_bib13","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pathol-011110-130321","article-title":"The HIF pathway and erythrocytosis","volume":"6","author":"Lee","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib15","first-page":"95A","article-title":"FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemia stage 3\/4 CKD patients","volume":"21","author":"Besarab","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.11.021_bib16","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1182\/blood-2007-02-073254","article-title":"HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques","volume":"110","author":"Hsieh","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.ajkd.2015.11.021_bib17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1053\/j.ajkd.2015.11.021_bib18","doi-asserted-by":"crossref","first-page":"e25324","DOI":"10.1371\/journal.pone.0025324","article-title":"Hepcidin is involved in iron regulation in the ischemic brain","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1053\/j.ajkd.2015.11.021_bib19","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1093\/ndt\/gfs322","article-title":"Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease","volume":"27","author":"Niihata","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2015.11.021_bib20","first-page":"203A","article-title":"Modulation of erythropoietin by prolyl hydroxylase inhibitor in a repeat dose, randomized placebo controlled trial","volume":"23","author":"Brigandi","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.11.021_bib21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ndt\/gfr431","article-title":"Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study","volume":"27","author":"Uehata","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2015.11.021_bib22","first-page":"390A","article-title":"Prolyl hydroxylase inhibitior modulation of erythropoietin in a randomized placebo controlled trial","volume":"21","author":"Brigandi","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib23","first-page":"203A","article-title":"Modulation of erythropoietin by prolyl hydroxylase inhibitor in renal impaired patients in a single dose cross-over study","volume":"23","author":"Brigandi","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib24","first-page":"524A","article-title":"Beneficial pharmacodynamic effects resulting from 'complete erythropoiesis' induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592","volume":"19","author":"Klaus","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib25","unstructured":"No authors listed. AKB-6548 clinical development. akebia.com\/programs\/akb-6548\/clinical-development\/. Accessed September 12,\u00a02014."},{"key":"10.1053\/j.ajkd.2015.11.021_bib26","first-page":"483A","article-title":"Induction of renal and extra-renal erythropoietin production by orally bioavailable HIF prolyl hydroxylase inhibitors","volume":"16","author":"Wang","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.11.021_bib27","first-page":"515A","article-title":"The prolylhydroxylase inhibitor FG2216 stimulates EPO production in nephric and anephric dialysis patients - evidence for an underutilized production capacity in liver and kidneys","volume":"18","author":"Bernhardt","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861501495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263861501495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:47:55Z","timestamp":1759459675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263861501495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S027263861501495X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.11.021","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Hypoxia-Inducible Factor\u2212Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}